By Marie Rosenthal, MS
There are metabolic differences after switching to dolutegravir-lamivudine (DTG/3TC; Dovato, ViiV Healthcare) from a three- or four-drug antiretroviral therapy regimen, but most are small or similar between treatment groups, according to Debbie P. Hagins, MD, the medical director at the Coastal Care Centers, in Savannah, Ga., who provided data at CROI 2022.
“The two-drug regimen of dolutegravir-lamivudine gives patients the opportunity to control HIV with fewer